双剂量艾考糊精对老年递增式持续不卧床腹膜透析患者的随机对照试验
DIDo研究为前瞻性随机试验,在老年新入递增式持续不卧床腹膜透析患者中比较每日2袋与1袋艾考糊精的优越性与安全性。第9个月时双剂量组与单剂量组终止每日3次交换的比例相似(16例[39%] vs 21例[50%];HR 0.69;95%CI 0.35-1.33),双剂量组净超滤更高且高渗透析液使用更少,两组安全事件发生率相似。
要点
- 双剂量艾考糊精未减少主要复合终点发生,第9个月HR 0.69(95%CI 0.35-1.33)。
- 双剂量组净超滤更高,高渗透析液使用更少。
- 两组腹膜炎、住院、残余尿量下降及严重不良事件发生率相似。
核心结论
- 在老年递增式持续不卧床腹膜透析患者中,双剂量艾考糊精与单剂量相比未降低主要结局发生率。
- 双剂量艾考糊精组观察到净超滤显著增强,未发现安全性问题。
研究设计与样本
- DIDo研究为前瞻性随机试验,比较每日2袋与1袋艾考糊精延长老年新入递增式(每日3袋)持续不卧床腹膜透析时长的优越性与安全性。
- 经过2个月导入期后,患者随机分为双剂量组(每日2袋艾考糊精+1袋葡萄糖透析液)和单剂量组(每日1袋艾考糊精+2袋葡萄糖透析液)。
- 双剂量组41例,单剂量组42例,两组基线特征均衡。
- 主要终点为第9个月时高渗透析液过度使用、转为其他透析模式(自动化腹膜透析、非递增式持续不卧床腹膜透析或血液透析)或死亡的复合终点。
- 次要终点包括第18个月时死亡率、每日超滤量、技术生存率、腹膜炎和住院率及安全性。
主要发现
- 第9个月时,双剂量组终止每日3次交换的患者比例为16例(39%),单剂量组为21例(50%),两组相似(HR 0.69;95%CI 0.35-1.33)。
- 第18个月时结果与第9个月相似。
- 双剂量艾考糊精组净超滤更高,高渗透析液使用更少。
- 两组腹膜炎发生率、住院率、残余尿量下降及严重不良事件发生率相似。
关键数值与推荐
- 主要终点第9个月双剂量组16例(39%)vs 单剂量组21例(50%),HR 0.69(95%CI 0.35-1.33)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Icodextrin enhances ultrafiltration (UF) in patients on peritoneal dialysis (PD) but is restricted to 1 bag/d, according to regulatory authorities. The Double-Icodextrin Dose (DIDo) study is a prospective randomized trial investigating the superiority and safety of using 2 bags/d versus 1 bag/d of icodextrin to extend incremental (3 bags/d) continuous ambulatory PD (CAPD) duration in older incident patients. METHODS: After a 2-month "run-in" period, the patients were randomized to 2 icodextrin ("double dose") + 1 glucose or 1 icodextrin ("single dose") + 2 glucose dialysates daily. The primary end point was a composite of excessive use of hypertonic dialysates, transfer to another dialysis modality (automated PD [APD], nonincremental CAPD, or hemodialysis) or death at month 9. Secondary end points included mortality, daily UF, technique survival, rates of peritonitis and hospitalizations, and safety at month 18. RESULTS: Forty-one patients were randomized to double dose and 42 to single-dose icodextrin. Baseline characteristics were well-balanced between groups. At month 9, the proportion of patients who discontinued 3 exchanges/d was similar between those receiving the double and the single icodextrin dose (16 [39%] vs. 21 [50%]; HR: 0.69; 95% confidence interval: 0.35-1.33). The results were similar at month 18. Patients in the double dose icodextrin had higher net UF and less hypertonic dialysates use. Rates of peritonitis, hospitalizations, residual urine output decline and serious adverse events (SAEs) were similar between both groups. CONCLUSION: In older patients on incremental CAPD, the double icodextrin dose did not reduce the primary outcome incidence compared with the single icodextrin dose. Significantly enhanced UF was observed in the double icodextrin dose group and no safety issue was identified.
引用
- Goffin E, Béchade C, Courivaud C, et al. The Double-Icodextrin Dose Randomized Controlled Trial of a Double Icodextrin Dose for Older Patients on Incremental Continuous Ambulatory Peritoneal Dialysis. Kidney Int Rep. 2025. PMID: 40814622. doi:10.1016/j.ekir.2025.05.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。